Rodyti trumpą aprašą

dc.contributor.authorJudickas, Šarūnas
dc.contributor.authorStasiūnaitis, Raimundas
dc.contributor.authorŽučenka, Andrius
dc.contributor.authorŽvirblis, Tadas
dc.contributor.authorŠerpytis, Mindaugas
dc.contributor.authorŠipylaitė, Jūratė
dc.date.accessioned2023-09-18T16:11:02Z
dc.date.available2023-09-18T16:11:02Z
dc.date.issued2021
dc.identifier.issn1010-660X
dc.identifier.urihttps://etalpykla.vilniustech.lt/handle/123456789/112170
dc.description.abstractBackground and Objectives: Oncohematological patients have a high risk of mortality when they need treatment in an intensive care unit (ICU). The aim of our study is to analyze the outcomes of oncohemathological patients admitted to the ICU and their risk factors. Materials and Methods: A prospective single‐center observational study was performed with 114 patients from July 2017 to December 2019. Inclusion criteria were transfer to an ICU, hematological malignancy, age >18 years, a central line or arterial line inserted or planned to be inserted, and a signed informed consent form. Univariate and multivariable logistic regression models were used to evaluate the potential risk factors for ICU mortality. Results: ICU mortality was 44.74%. Invasive mechanical ventilation in ICU was used for 55.26% of the patients, and vasoactive drugs were used for 77.19% of patients. Factors independently associated with it were qSOFA score ≥2, increase of SOFA score over the first 48 h, mechanical ventilation on the first day in ICU, need for colistin therapy, lower arterial pH on arrival to ICU. Cut‐off value of the noradrenaline dose associated with ICU mortality was 0.21 μg/kg/min with a ROC of 0.9686 (95%CI 0.93–1.00, p < 0.0001). Conclusions: Mortality of oncohematological patients in the ICU is high and it is associated with progression of organ dysfunction over the first 48 h in ICU, invasive mechanical ventilation and need for relatively low dose of noradrenaline. Despite our findings, we do not recommend making decisions regarding treatment limitations for patients who have reached cut‐off dose of noradrenaline.eng
dc.formatPDF
dc.format.extentp. [1-12]
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyMEDLINE
dc.relation.isreferencedbyEmbase
dc.rightsLaisvai prieinamas internete
dc.source.urihttps://www.mdpi.com/1648-9144/57/12/1317/htm
dc.source.urihttps://talpykla.elaba.lt/elaba-fedora/objects/elaba:112724581/datastreams/MAIN/content
dc.titleOutcomes and risk factors of critically ill patients with hematological malignancy. prospective single‐centre observational study
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.licenseCreative Commons – Attribution – 4.0 International
dcterms.references37
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionVilniaus universitetas
dc.contributor.institutionVilniaus Gedimino technikos universitetas
dc.contributor.facultyMechanikos fakultetas / Faculty of Mechanics
dc.subject.researchfieldM 001 - Medicina / Medicine
dc.subject.researchfieldT 009 - Mechanikos inžinerija / Mechanical enginering
dc.subject.studydirectionG01 - Medicina / Medicine
dc.subject.enblood cancer
dc.subject.enoncohematological patients
dc.subject.enintensive care unit
dc.subject.enoutcome
dc.subject.enBaltic region
dcterms.sourcetitleMedicina
dc.description.issueiss. 12
dc.description.volumevol. 57
dc.publisher.nameMDPI
dc.publisher.cityBasel
dc.identifier.doi000735438500001
dc.identifier.doi10.3390/medicina57121317
dc.identifier.elaba112724581


Šio įrašo failai

Thumbnail

Šis įrašas yra šioje (-se) kolekcijoje (-ose)

Rodyti trumpą aprašą